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THE RETINAL PIGMENT EPITHELIAL CELLS MODULATE 
PHAGOLYSOSOME ACTIVATION IN MACROPHAGES THROUGH 
NEUROPEPTIDES, A-MSH AND NPY  
YOONA CHOE 
ABSTRACT 
Objective: The main function of the human eye is to detect light, motion, and color from 
our surroundings. This information is then processed and translated in the brain as vision. 
However, what is less known about the eye is its ability to regulate immune function. It is 
this ocular immune privilege that maintains the eye’s ability collect visual information. 
The degeneration of immune privilege causes inflammation, which can cause damage to 
the eye, an increased susceptibility of eye disorders such as autoimmune uveitis 
(inflammation of the uvea), and may lead to vision impairment. Research in ocular 
immune privilege can open up potential clinical applications for maladies such as uveitis, 
septic shock, hypersensitivity, multiple sclerosis and allograft survival. Previous research 
has shown the importance of the retinal pigment epithelial (RPE) cells for maintenance of 
ocular immune privilege, and has identified the use of neuropeptides to suppress 
inflammatory responses in macrophages. This project aims to study the role and 
mechanism of the RPE cells in phagolysosome activation in macrophages that mediate 
inflammation.  
Methods: Posterior eyecups were prepared from eyes of healthy, EAU immunized, or 
post-EAU mice. Eyecups, which consisted of the sclera, choroid, and a single layer of 
RPE, were cultured in serum-free media (SFM). During a 24-hour incubation period, 
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peritoneal macrophages were collected intraperitoneal (IP) and cultured. Conditioned 
media (CM) was applied to the collected macrophages along with pHrodo-red opsonized 
bioparticles and were incubated for 24-hours in 37°C. After incubation, cells were 
examined by fluorescent microscopy for phagolysosome activation. Also, this was also 
done with RPE CM depleted of α-MSH, NPY, and α-MSH + NPY. A viability assay was 
performed on macrophages treated with depleted RPE CM to investigate the possibility 
that removing the neuropeptides will induce cell death. To examine the cytokines 
involved in RPE CM—from healthy, EAU and post-EAU mice—modulation of 
phagolysosome activation, a mouse cytokine array was performed that assessed for 
twenty different mouse cytokines. 
Results: Results from fluorescent microscopy showed that healthy RPE CM caused 
significant suppression of phagolysosome activity in macrophages. The RPE CM 
depleted of α-MSH, NPY, and α-MSH + NPY showed a significant suppression of 
phagolysosome activity in macrophages. However, these results may have been 
misrepresented as the macrophages treated with depleted RPE CM were non-viable. RPE 
CM from EAU mice showed the inability to down-regulate phagolysosome activity while 
RPE CM from post-EAU mice recovered its ability to down-regulate phagolysosome 
activity. The mouse cytokine array of RPE CM from healthy, EAU and post-EAU mice 
identified keratinocyte-derived cytokine (KC), high concentrations of interleukin-6 (IL-
6), trace amounts of vascular endothelial growth factor (VEGF), and no other pro or anti-
inflammatory cytokines.  
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Conclusions: Healthy RPE cells suppress phagolysosome activation in activated 
macrophages. In contrast, RPE cells from mice with active EAU lose its ability to 
regulate phagolysosome activation, but regain this ability when the disease resolves 
following α-MSH treatment. RPE CM from post-EAU mice treated with MC5r agonist 
did not recover suppression of phagolysosome activation which suggests that α-MSH 
causes suppression of phagolysosome activation through other melanocortin receptors or 
that this suppression requires other mechanisms in conjunction to MC5r stimulation. 
Cytokine IL-6 may be involved in RPE suppression of phagolysosome activation; 
however, further study will have to be done. The results demonstrate that part of the 
mechanisms of ocular immune privilege is the tight control by RPE of the phagocytic 
process in macrophages. It is possible that this contributes to ocular immune privilege 
minimizing the potential of processing and presenting self-proteins, and to allow for 
clearance of harmful materials while suppressing the activation of inflammation.   
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INTRODUCTION 	  
The immune system is essential to help identify and remove pathogens in all 
living organisms and tissues. However useful to health, complications to the immune 
system may cause disease or pathology (Streilein, 1997). Ocular pathology caused by 
immunity is infrequent because immune responses are highly controlled (Streilein, 1997). 
By studying the intrinsic mechanisms behind ocular regulation of immunity would not 
only help remedy autoimmune diseases, but also advance clinical outcomes to other 
immune mediated diseases (A.W. Taylor, 2009).  
The Importance of Immune Privilege 
The term “immune privilege,” first conceived by Sir Peter Medawar in the 1940s 
(Medawar, 1945; A. W. Taylor & Kaplan, 2010), is defined as a site or tissue where a 
foreign organ or tissue graft can exist in a prolonged or an unlimited amount of time (J. 
W. Streilein, 2003). While immune regulation occurs in all organs and tissues, there exist 
several sites that possess immune privilege (Table 1). Medawar observed skin allografts 
positioned in the ocular anterior chamber (AC) of rabbits. He found that even though 
these rabbits were first immunized to reject skin allografts, these allografts experienced 
an extended survival time (Medawar, 1945, 1948). It was also Medawar who assigned 
this privilege to be an attribute of a specific tissue or site and hypothesized that immune 
privilege may be a consequence of an “immunologic ignorance” due to blood:tissue 
barriers that exist around the brain and eyes (Streilein, Okamoto, Sano, & Taylor, 2000; 
A. W. Taylor & Kaplan, 2010). Since then, researchers have found that while the 
blood:tissue barrier partially constitutes a passive or innate part of the immune privilege, 
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there is also an active or adaptive part of immune privilege (Kaplan & Streilein, 1977; 
Streilein et al., 2000; A. W. Taylor, 2003). 
Table 1. A Reduced List of Immune Privileged Sites and Tissues 
Sites Tissues 
Eye: cornea, anterior chamber, vitreous cavity and 
subretinal space 
Eye: cornea, lens, pigment epithelium and 
retina 
Brain: ventricles and striatum Brain and spinal cord 
Pregnant uterus Placenta 
Ovary Ovary 
Testis Testis 
Adrenal cortex Liver 
Hair follicles  
Hamster cheek pouch Hamster cheek pouch 
Certain tumors Certain tumors 
 
Note. From “Ocular Immune Privilege: Therapeutic Opportunities From An Experiment of Nature,” by J. 
W. Streilein, 2003, Nature Reviews Immunology, 3(11), p. 880.  
Immune Privilege of the Eye 
The human eye functions to detect light, motion, and color that is processed and 
translated in the brain as visual information. What is less known about the eye is its 
capability to regulate immune function. This ability is referred to as the ocular immune 
privilege. Immune privilege largely contributes to the eye’s maintenance of an anti-
inflammatory microenvironment while constantly exposed to outside elements (Strauss, 
2005).  The degeneration of immune privilege has been known to cause damage to the 
eye and leads to an increased susceptibility to eye disorders such as uveitis (inflammation 
of the uvea) (A. W. Taylor & Kaplan, 2010). The main structures that contribute to the 
eye’s immune privilege are the epithelium at the edge of the cornea, vessels of the iris, 
ciliary body and retina. This constitutes the blood:ocular barrier and strictly regulates the 
molecules and cells that enter the eye. What is also unique about the eye is the absence of 
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direct lymphatic drainage pathways. Because lymph vessels are the main pathway by 
which most antigens first come across T and B cells, the absence of lymphatic drainage 
shields ocular antigens from the immune system (Streilein, 1997). Medawar hypothesized 
that this, along with the blood:ocular barrier, was the reason the eye is immune 
privileged; however, while the lack of lymphatic drainage is a significant portion of its 
passive privilege, it does not entirely explain the reduced immune reaction to antigens in 
or from the eye (Streilein, 2003b).  
Adaptive Immune Privilege 
In the 1970’s, researchers found that injecting allogeneic lymphoid cells into the 
anterior chamber of rat eyes caused an abnormal immune response. Rather than cause a 
rejection of foreign substances and tissues, the injection stunted the ability to reject 
orthotopic skin grafts with identical alloantigens. More specifically, it induced a 
suppressor immunity of antigen-specific efferent suppressor CD8 T cells and afferent 
suppressor CD4 T cells, now established as T regulatory (Treg) cells (Kaplan & Streilein, 
1977; Streilein, 2003a). In 1981, researchers discovered that injecting allogeneic tumor 
cells into the AC of mice eyes allowed the growth of tumors in the eyes; more 
importantly, the mice were not able to reject orthotopic donor-specific skin grafts with 
the same allogeneic antigen expression as the tumor cells (Niederkorn, Streilein, & 
Shadduck, 1981). These experiments not only confirmed that ocular immune privilege 
existed but also paved the way for other researchers to explore ocular immune privilege 
(Streilein et al., 2000).   
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In the past forty years, more adaptive mechanisms of ocular immune privilege 
have come to light. In a normal immune response, when inoculated with antigens, the 
host would develop a donor-specific delayed-type hypersensitivity (DTH). However, the 
placement of antigens in an immune privileged site failed to produce such 
hypersensitivity response. More specifically, the placement of antigens in the anterior 
chamber failed to induce DTH (Streilein, Niederkorn, & Shadduck, 1980). This 
distinctive suppressor immunity response is called Anterior Chamber-Associated Immune 
Deviation (ACAID) (Streilein, Ksander, & Taylor, 1997).  
ACAID can be instigated by the placement of antigens in the AC, subretinal 
space, or vitreous cavity. The instigation of ACAID requires that the antigen be injected 
into a specific ocular compartment, the spleen be intact for the first seven days, and the 
eye be intact for the first four days (Kaplan & Streilein, 1977). We also understand that 
ACAID is mediated by antigen presenting cell (APC), F4/80 macrophage, that presents 
the antigen to CD4 and CD8 T cells, B cells, and NKT cells in the spleen (D’Orazio & 
Niederkorn, 1998; Lin et al., 2005, p. 4; Sonoda & Stein-Streilein, 2002). Later studies 
showed that there are an abundance of immunosuppressive molecules and modulatory 
factors in the aqueous humor that impact the action of immune cells including affecting 
the presentation of antigens on APCs to produce a suppressor immunity (A. W. Taylor, 
2002).  
The aqueous humor, which fills the AC, is a fluid that was found to suppress 
immune activity when applied to macrophages (Wilbanks & Streilein, 1992). It is also 
known to suppress T-cell activation and proliferation (Kaiser, Ksander, & Streilein, 
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1989), inhibit IFN-γ production by activate CD4 T cells (Andrew W. Taylor, Alard, Yee, 
& Streilein, 2007), and even impede NK cell-mediated lysis (Apte, Sinha, Mayhew, 
Wistow, & Niederkorn, 1998).  
Neuropeptides and Ocular Immunity 
 The aqueous humor consist of neuropeptides, complement factors and their 
inhibitors, proteins, and other molecules that all compose an ocular microenvironment 
that allows the maintenance and regulation of the constant potential inflammation and 
necrosis of the eye (A.W. Taylor, 2009). A large portion of the array of regulating and 
immunosuppressive factors is neuropeptides. A few of these neuropeptides include 
vasoactive intestinal peptide (VIP) (A. W. Taylor, Streilein, & Cousins, 1994), α-
melanocyte stimulating hormone (α-MSH) (A. W. Taylor, 2005), somatostatin (Andrew 
W. Taylor & Yee, 2003), and calcitonin gene-related peptide (CGRP) (A. W. Taylor, 
Yee, & Streilein, 1998). 
α-MSH was the first reported immunomodulating neuropeptide in the eye (A. W. 
Taylor, Streilein, & Cousins, 1992). It is a thirteen amino acid long peptide that is 
released from proopiomelanocortin hormone (POMC) through endoproteolytic cleavage 
and posttranslational modifications. It is mainly known for its function in inducing 
melanin. However, what is less known is that α-MSH has a chief role in regulating 
defense mechanisms in mammals. α-MSH along with CGRP and cytokine transforming 
growth factor-β2 (TGF-β2) has been shown to inhibit inflammatory activation in 
macrophages. They have been shown to inhibit inflammatory activity by suppressing 
endotoxin-induced inflammatory activity, and also promote an anti-inflammatory 
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cytokine production by the macrophages (A. W. Taylor et al., 1998). α-MSH with Fas 
ligand and TGF-β2 may also control the recruitment of macrophages and neutrophils 
(Catania et al., 1996; Griffith, Brunner, Fletcher, Green, & Ferguson, 1995; Masli, 
Turpie, Hecker, & Streilein, 2002). Also, α-MSH has been found to induce its own 
synthesis as well as its melanocortin receptors on macrophages, and thus further 
contribute to the suppression of inflammation in macrophages through a sustained 
autocrine loop (Rajora et al., 1996).  
While these findings imply that α-MSH can regulate suppression of inherent-
mediated inflammation, α-MSH is also involved in the regulation of adaptive immune-
mediated inflammation. α-MSH modulates T-cells activities. For example, α-MSH 
inhibits the synthesis of interferon-γ (IFN-γ) by effector T-cells. It is through α-MSH, 
with the help of TGF-β2, which aqueous humor modulates T-cell response from pro-
inflammatory to non-inflammatory activity (Nishida & Taylor, 1999). Interestingly, α-
MSH also alternatively activates macrophages consequently promoting suppression and 
tolerance when they act as APCs (Lau & Taylor, 2009; T. A. Luger, Kalden, Scholzen, & 
Brzoska, 1999).  The constant growth of new information about α-MSH and its regulation 
of immunity continue to prove its importance.  
 Another important neuropeptide involved in anti-inflammatory mechanisms is 
neuropeptide Y (NPY). NPY is a 36 amino acid long sympathetic neurotransmitter 
peptide that innervates immune organs as well as leukocytes (Bedoui, von Hörsten, & 
Gebhardt, 2007; Dimitrijević & Stanojević, 2013; Petitto, Huang, & McCarthy, 1994). 
Studies have found that in vitro NPY increased different tasks of inflammatory cells such 
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as chemotaxis, production of nitric oxide and reactive oxygen metabolites, secretion of 
cytokines as well as simple adherence (Mitić, Stanojević, Kuštrimović, Vujić, & 
Dimitrijević, 2011). NPY has also been reported to have inhibitory effects on 
inflammatory cell activity. Specifically, NPY reduces phagocytosis (Bedoui et al., 2007) 
and granulocyte oxidative burst (Dimitrijević et al., 2006). What is important about NPY 
in regards to ocular immunity, however, is that researchers have discovered that survival 
and function of macrophages is reliant on not just NPY but also α-MSH, both produced 
by the retinal pigment epithelium (RPE) (Kawanaka & Taylor, 2011). 
Retinal Pigment Epithelium as an Immune-Privileged Tissue 
One of the primary roles of the RPE is visually related. It is made of cuboidal 
epithelium composed of microvilli on the apical side thus projecting out to the to meet 
with the rod and cone photoreceptors. The RPE also functions in metabolism and 
transportation which is crucial to maintain homeostasis and ultimately visual capabilities 
of the eye (Bok, 1993). Because the RPE forms an epithelium of tight junctions between 
the photoreceptors and choroicapillaris (Figure 1), it acts as part of a blood-retinal barrier 
isolating the inner retina from the rest of the systemic circulation while also controlling 
which nutrients and metabolites are allowed to cross the barrier. The RPE also mediates 
phagocytosis of photoreceptors tips that have been shed as well as regeneration of the 
retinoids (Bok, 1993; Steinberg, 1985; Strauss, 2005). In fact, the apical surface of just 
one RPE cell supports about 30 to 50 photoreceptors outer segments. The basal surface of 
the RPE, which is attached to Bruch’s membrane, specializes in exchanging nutrients and 
	  8 
metabolites with the choroid (Bonilha, 2008). As discussed earlier, such features of the 
RPE structure helps to sustain the passive ocular immune privilege.  
 
Figure 1. Diagram of the blood-retinal barrier locating the RPE in relation to the photoreceptors and 
choroid. Adapted from Science Of AMD, n.d., Retrieved March 12, 2015, from 
http://www.scienceofamd.org/learn/. Copyright 2015 The Angiogenesis Foundation.  
The RPE also supports ocular immune privilege by its ability to interact with the 
immune system with the function of suppressing or activating immune response in the 
healthy eye. More specifically, RPE cells have been proven to down-regulate T-cell 
activation by direct cell contact as well as production of immunosuppressive factors 
(Ishida, Panjwani, Cao, & Streilein, 2003; Sugita et al., 2009). Additionally, as previously 
mentioned, the RPE produce neuropeptides such as α-MSH and NPY. These 
neuropeptides, along with other immunomodulating factors, are known to affect immune 
cell functions (Kawanaka & Taylor, 2011). Specifically, it was discovered that α-MSH 
and NPY control proinflammatory signals and signal the alternative activation 
mechanisms of macrophages. What is more, it has recently been discovered that α-MSH 
with NPY prompts myeloid suppressor cell-like activity in macrophages at rest and also 
helps monitor the same activity in retinal microglial cells (Kawanaka & Taylor, 2011). 
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Past research indicates that there are four melanocortin receptors α-MSH binds to 
in the body. In the neural retina of the eye, MC3r, MC4r, and MC5r are expressed. The 
RPE expresses melanocortin receptors MC1r and MC5r (Lindqvist, Näpänkangas, 
Lindblom, & Hallböök, 2003). In fact, the hypothesis that α-MSH prompts Treg cells in 
vivo was via MC5r knocked-out mice. After being re-immunized post-recovery from the 
first incidence of experimental autoimmune uveitis (EAU), these mice not only had a 
second incidence of EAU but with rapid onset and increased severity. The failure for 
MC5r knockout mice to establish a post-EAU suppressive immunity, as seen in wild type 
mice, proved this failure was due to the inability to produce EAU regulatory APCs (Lee 
& Taylor, 2011).  
Murine EAU as a Model for Intraocular Inflammation 
 Uveitis is an intraocular inflammatory disease that is evoked by a large array of 
etiologies (A. W. Taylor & Kaplan, 2010). The most observed animal model of 
intraocular inflammation is EAU. EAU can be induced by immunizing in rodents with 
specific retinal proteins like interphotoreceptor retinoid binding protein (IRBP), 
phosducin, or rhodopsin (Gery et al., 1986; Schalken et al., 1988). For EAU to be 
induced, the ocular-autoantigen specific effector T cells must expand either through 
knocking out tolerance in the eye or adjuvant-mediated immunization (A. W. Taylor & 
Kaplan, 2010). When EAU does occur, it is apparent that the immunosuppressive ocular 
microenvironment is no longer prevalent. Studies of the effects from EAU have shown 
that even before inflammation is observed, pro-inflammatory cytokines are already 
present and the aqueous humor no longer possess immunosuppressive capabilities. The 
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loss of immunosuppression is brief, however, and ocular immune privilege is restored 
when intraocular inflammation ceases (Ohta, Wiggert, Yamagami, Taylor, & Streilein, 
2000).  
Specific Aims 
Studies have demonstrated that neuropeptides, α-MSH and NPY suppress 
phagolysosome activity in macrophages. Researchers also discovered that both 
neuropeptides are produced by the RPE. Therefore, there is potential that the RPE, 
through the synthesis of α-MSH and NPY, may elicit immunosuppression in 
macrophages. Therefore, it is our objective to determine: 
1. Does RPE suppress phagolysosome activation in primary macrophages; 
therefore, inhibit innate immunity 
2. Whether neuropeptides α-MSH and NPY are factors in phagolysosome 
suppression; 
3. In EAU immunized mice, does RPE suppress phagolysosome 
activation in primary macrophages; 
4. In post-EAU mice, does RPE suppress phagolysosome activation in 
primary macrophages; 
5. Does treating EAU with α-MSH and/or MC5r agonist restore RPE 
suppression of phagolysosome activity in primary macrophages; 
6. What cytokines may be released by the RPE in EAU that could 
neutralize suppression of phagolysosome activation. 
	  11 
METHODS 
 
Preparation of Posterior Eyecups 	   Eyecups were prepared as described previously (Lau & Taylor, 2009; Zamiri, 
Masli, Streilein, & Taylor, 2006). Eyes from euthanized mice were extracted and placed 
on ice in phosphate buffered saline (PBS) (Lonza, Walkersville, PA) for approximately 
30 minutes. After removal of the connective tissue, muscles, and conjunctiva, a 
circumferential incision posterior the ciliary body was conducted. The anterior portion of 
the eye, which includes the ciliary body, lens, cornea, and iris, was discarded. The neural 
retina was then removed from the monolayer of RPE by microsurgical forceps leaving 
the final product—the posterior eyecup. Each posterior eyecup, consisting of the choroid, 
sclera, and a single layer of RPE, were placed into separate wells of a 96-well round-
bottom culture plate. The eyecups were submerged in 100 µL of serum-free media (SFM) 
containing DMEM (Lonza, Walkersville, PA), 0.1 M HEPES, NEAA, 4.5 g/L Glucose, 
L- glutamine, sodium pyruvate, 1% gentamicin, 0.1% bovine serum albumin (Sigma 
Chemical, St. Louis, MO), and supplemented with 0.1 x ITS+ solution (Sigma Chemical, 
St. Louis, MO). The conditioned media (CM) from within the eyecup was removed 24 
hours after incubation. The CM was then used in the phagocytosis assays. 
Phagolysosome Activity Assay 
The macrophages were collected by injecting and then recovering 5ml PBS 
directly from the non-irritated peritoneal cavity. Upon extraction, the peritoneal 
macrophages were centrifuged at 1200 RPM for 10 minutes at 4°C, and suspended in 
400µl Roswell Park Memorial Institute (RPMI)-1640 with L-Glutamine (Lonza, 
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Walkersville, PA) and 10% FBS to assess cell purity and viability. An amount of 500µl 
of peritoneal macrophages at a concentration of 2.5x105 cells/ml was distributed into 
each well of an 8-welled glass slide. The cultures were incubated for 1-2 hours at 37°C in 
10% CO2. The slides were washed with SFM before the resting macrophage cultures 
were finally cultured in 200µl of CM for 24 hours at 37°C, 10% CO2 humidified 
incubator. The macrophages were treated with SFM containing α-MSH and NPY at 1 
ng/ml each. This is the concentration of the neuropeptides in conditioned media produced 
in 24 hours by organotypic healthy RPE monolayer cultures. Also added 30 minutes into 
the incubation period were 1-2µl of opsonized Escherichia coli pHrodo-red fluorescent 
bioparticles, which increase in fluorescence at acidic pH, such as the internal 
compartment of an activated phagolysosome. Opsonized pHrodo bioparticles were 
prepared with 1:1 mixture of pHrodo red E.coli bioparticles conjugate (Life 
Technologies-Molecular Probes, Grand Island, NY) and E.coli bioparticles opsonizing 
reagent (Life Technologies-Molecular Probes, Grand Island, NY).  
Depletion of Neuropeptides 
To characterize the effects of individual neuropeptides, α-MSH, NPY, or both α-
MSH and NPY were depleted from the RPE CM before the CM was used to treat the 
macrophages. To deplete α-MSH and NPY, antibodies against α-MSH, or NPY from 
Peninsula Laboratories (San Carlos, CA) were added to the CM. For controls, we used an 
irrelevant immunoglobin (IgG) MC3-R rabbit polyclonal IgG (Santa Cruz Biotechnology, 
Santa Cruz, CA). The CM with added antibody was incubated at 4°C for 1 hour, protein-
G coated beads (Santa Cruz Biotechnology) were added to the CM and incubated for an 
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additional 1 hour 4°C. The beads were centrifuged down at 2000 RPM for 2 minutes and 
the neuropeptide-depleted supernatant (absorbed CM) was used to complete the 
phagocytosis assays. Antibody concentrations were used at 10 - 100x their neutralizing 
dose (2µl/100µl of CM). 
Viability Assay 
Once CM or absorbed CM were incubated for a 24-hour period, a fluorescent probe, 
CellTracker Green CMFDA (5-chloromethylfluorescein diacetate) (Life Technologies, 
Grand Island, NY), was used to measure and quantify viability of macrophages. The 
CellTracker fluorescent probe was designed to passively cross the cell membranes and 
will only fluoresce at physiological pH. The fluorescent probe was diluted to a final 
working concentration of 10µM. The probe and CM was incubated at 37°C in 10% CO2 
for 30 minutes before fluorescence was measured.  
Immunization and Treatment of EAU Mice 
 Mice were immunized with EAU by 200µl injections of 1:1 Complete Freund 
Adjuvant (CFA) (DIFCO Laboratories, Detroit, MI) with interphotoreceptor retinoid 
binding protein (IRBP) (GenScript, Piscataway, NJ) emulsions (2mg/ml) followed by 
200µl injections of pertussis toxin (Sigma-Aldrich, St. Louis, MO). All injections were 
subcutaneous. EAU manifestations were tracked and scored based on a 0-5 scale. An eye 
with a 0 score showed no signs of EAU while eyes with a score of 5 showed massive 
scarring and inflammation. When all mice showed an EAU score of 3 or 4, injections of 
α-MSH (30µg/ml), MC5r agonist (1µg/ml), or PBS were given IP. Mice were sacrificed 
study only after they were given a score of 0 or 1.  
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Fluorescent Microscopy for Phagolysosome Activation 
 To image the macrophages by fluorescent microscopy, after a 24-hour incubation 
period, the cultured macrophages were washed once with 0.01M PBS and 200µl of PBS 
was added to each well in the 8-welled glass slide. The macrophage cultures were 
digitally imaged with the FSX100 digital fluorescent microscope (Olympus, Center 
Valley, PA) using a 40x objective lens. A range of 1/50-1/200 second exposure time was 
used for phase contrast. For red fluorescence (pHrodo bioparticles), a range of 1/1.5-1/2 
second exposure time was used. For green (viability probe) fluorescence, a 1/2-1/2.5 
second exposure time used. These images were corrected for background and overlaid to 
make the presented images using the FSX100 software. The corrected total cellular 
fluorescence (CTCF) was calculated and used to quantify the degree of phagolysosome 
activation. 
Mouse Cytokine Array Assay 
 In order to identify and measure which cytokines were present in RPE CM, the 
Quantibody Mouse Cytokine Array 1 (RayBiotech, Inc., Norcross, GA) was used to 
quantify 20 different mouse cytokines. This cytokine array was performed in a two day 
period allowing for a 24-hour incubation period at 4°C for blocking. Images were taken 
at an exposure time of 50.05 seconds. Images and concentration analysis were determined 
using Quantity One 4.6.9 software (Bio-Rad Laboratories, Hercules, CA).  
Data and Statistical Analysis  
All values were stored in an Excel Spreadsheet (Microsoft, 2014). However, 
statistical analysis calculations were performed using Prism software (GraphPad 
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Software Inc., La Jolla, CA). Statistical differences for fluorescence were calculated by 
non-parametric one-tailed t-test (Mann-Whitney) and transformed for relative CTCF 
based off of mean CTCF of resting cells. The concentrations for mouse cytokines were 
determined by non-linear regression curves for best fit. Concentrations were found by 
interpolation from this standard curve. All significant differences were found at P ≤ 0.05.	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RESULTS 
 
RPE CM Effect on Phagolysosome Activation  
 To determine if there was an effect of the RPE CM on the activation of 
phagolysosomes in macrophages, the macrophages were treated with a 1:1 mixture of 
E.coli opsonizing agent and E.coli bioparticles to phagocytize. Once phagocytized, 
bioparticles were designed to fluoresce red as the pH dropped to acidic conditions. Using 
digital fluorescence microscopy, live images were taken after a 24-hour incubation period 
(Figure 2).  
A.      B. 
          
Figure 2. Images of macrophages untreated and treated by RPE CM. (A) Image of primary 
macrophages at rest without pHrodo-red bioparticles. (B) Image of primary macrophages with pHrodo-red 
bioparticles and untreated by RPE CM.  
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Figure 2C. Image of primary macrophages with RPE CM.  
The untreated macrophages phagocytized and moved the bioparticles to active 
phagolysosomes, and thus were bright red (Figure 2B). Very little red fluorescence was 
seen in RPE CM treated macrophages (Figure 2C).  This suggests that RPE CM may be 
suppressing phagolysosome activation in the macrophages. To quantify the effects of the 
RPE CM on macrophages activation or suppression of phagolysosome activity, cells were  
 
Figure 3. The effects of RPE CM on phagolysosome activity in macrophages. The macrophages were 
treated with RPE CM and opsonized E.coli pHrodo-red-conjugated bioparticles. After 24-hours of 
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incubation at 37°C, macrophages were washed with 0.01M PBS and analyzed by fluorescent microscopy. 
Shown is the relative CTCF ± SEM of pHrodo-red expression in the RPE CM treated macrophages 
compared to the pHrodo-red expression in untreated macrophages. Data is from two separate experiments, 
N=8. *This group of treated to untreated macrophage was significantly different (P<0.05, P<0.0001).  
treated with RPE CM and opsonized E.coli pHrodo bioparticles on the macrophages. 
After the 24-hour incubation period, the macrophages were assayed for fluorescent 
intensity and relative corrected total cellular fluorescence (CTCF) was calculated. The 
relative CTCF was compared for phagolysosome activity (Figure 3). There was a 
significant difference between the relative CTCF expressed by untreated macrophages 
with relative CTCF expressed by macrophages treated with RPE CM. These results 
indicated that the macrophages treated by RPE CM significantly suppressed macrophage 
phagolysosome activation.  
Absorbed RPE CM Effect on Phagolysosome Activation  
 To see whether neuropeptides α-MSH and NPY are factors in phagolysosome 
suppression, the RPE CM was depleted of α-MSH, NPY, and both α-MSH + NPY. A 
rabbit polyclonal IgG against an irrelevant protein was used as a control. The primary 
macrophages were then treated with the now absorbed RPE CM. After incubation, digital 
microscopy was again used for live images showing fluorescence (Figure 4A-F). 
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A.      B. 
          
Figure 4. Images of macrophages treated with absorbed RPE CM. (A) Image of untreated primary 
macrophages at rest without pHrodo-red bioparticles (B) Image of primary macrophages with pHrodo-red 
bioparticles and untreated by absorbed RPE CM. Images are taken from two different experiments with 
same exposure settings. 
C.      D. 
          
Figure 4C-D. (C) Image of primary macrophages treated with –IgG absorbed RPE CM. (D) Image of 
primary macrophages treated with –αMSH absorbed RPE CM. Images are taken from two different 
experiments with same exposure settings. 
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E.      F. 
           
Figure 4E-F. (E) Image of primary macrophages treated with –NPY absorbed RPE CM. (F) Image of 
primary macrophages treated with –αMSH –NPY absorbed RPE CM. Images are taken from two different 
experiments with same exposure settings. 
The untreated macrophages demonstrated phagolysosome activation again 
showing a bright red fluorescence (Figure 4B). Macrophages treated by RPE CM 
depleted using an irrelevant IgG showed little fluorescence (Figure 4C). This 
demonstrated that the procedure to absorb the neuropeptides did not interfere with usual 
RPE CM activity. The absorbed RPE CM depleted of α-MSH (Figure 4D), NPY (Figure 
4E) or α-MSH + NPY (Figure 4F) showed even less fluorescence than those 
macrophages treated by irrelevant IgG, and were even comparable to macrophages that 
were not treated with any pHrodo bioparticles (Figure 4A). Macrophages that were 
treated with RPE CM absorbed of α-MSH, NPY and α-MSH + NPY exhibited signs of 
lost viability.  
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Figure 5. The effects of absorbed RPE CM on phagolysosome activity. The macrophages were treated 
with RPE CM –αMSH, -NPY, or –αMSH -NPY. After 24-hours of incubation at 37°C, macrophages were 
analyzed by fluorescent microscopy. Shown is the relative CTCF ± SEM of pHrodo-red expression in the 
absorbed RPE CM treated macrophages compared to the pHrodo-red expression in untreated macrophages. 
Data is from 5 separate experiments, N=5. *The group of untreated to RPE CM –MC3r treated macrophage 
were significantly different, P<0.05. **The groups of RPE CM –MC3r to RPE CM –αMSH, -NPY, -αMSH 
–NPY and untreated to RPE CM –αMSH, -NPY, -αMSH –NPY were significantly different, P<0.0001). 
To quantify the effects of phagolysosome activity of the macrophages, the cells 
treated with absorbed RPE CM were assayed for CTCF. The relative CTCF was 
compared for phagolysosome activity (Figure 5). There was a significant difference 
between the relative CTCF expressed by macrophages untreated with relative CTCF 
expressed by macrophages treated with relative CTCF of macrophages treated with RPE 
CM depleted with irrelevant IgG as well as relative CTCF of untreated macrophages with 
relative CTCF of macrophages treated with RPE CM depleted of α-MSH, -NPY, and α-
MSH + NPY. There was no significant difference between CTCF expression of 
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macrophages treated α-MSH, NPY or α-MSH + NPY. This further suggested that the 
macrophages treated with the depleted CM lost viability.  
Viability of Absorbed RPE CM and its Effect on Phagolysosome Activation  
 Macrophages treated with absorbed RPE CM depleted of α-MSH, NPY and α-
MSH + NPY showed no or very little fluorescence and abnormal appearance. This 
suggested potential loss of viability. To assess whether the viability of the macrophages, 
the previous study was repeated; however, after RPE CM or absorbed CM were 
incubated for a 24-hour period and prior to viewing results under fluorescent microscopy, 
a fluorescent probe, CellTracker Green CMFDA, was added to treated macrophages. The 
CellTracker fluorescent probe was designed to fluoresce green at physiological pH. The 
probe and macrophages treated with absorbed RPE CM were incubated at 37°C for 30 
minutes before fluorescence was measured (Figure 6A-F). 
A.      B. 
         
Figure 6. Images of macrophages treated with absorbed RPE CM and assayed for viability. (A) 
Image of untreated macrophages at rest with viability probe without pHrodo-red bioparticles. (B) Image of 
untreated macrophages with viability probe and pHrodo-red bioparticles. 
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C.      D. 
          
Figure 6C-D. (C) Image of macrophages treated with viability probe and IgG absorbed RPE CM. (D) 
Image of macrophages treated with viability probe –αMSH absorbed RPE CM. 
E.      F. 
        
Figure 6E-F. (E) Image of macrophages treated with viability probe and –NPY absorbed RPE CM. (F) 
Image of macrophages treated with viability probe and –αMSH –NPY absorbed RPE CM. 
The macrophages untreated by absorbed RPE CM or pHrodo bioparticles (Figure 
6A) showed no red fluorescence as it is null of pHrodo bioparticles, but were bright green 
fluorescence that indicated viable cells. Macrophages untreated by absorbed RPE CM but 
fed with pHrodo bioparticles (Figure 6B) show both red and green fluorescence. Areas 
that fluoresce both red and green manifest as an orange or yellow color. Looking at 
Figure 6C, which showed the macrophages treated with RPE CM depleted with an 
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irrelevant IgG, there were the same clear bright green fluorescence indicating viability. 
However, as was seen in the previous study, there was a decreased amount of red 
fluorescence demonstrating suppression of macrophage phagolysosome activation. The 
macrophages that were treated with RPE CM depleted of α-MSH (Figure 6D), NPY 
(Figure 6E) or α-MSH + NPY (Figure 6F) showed very little to no red fluorescence as 
well as little to no green fluorescence. This suggested that the RPE produce a soluble 
factor that promotes cell death that is blocked by α-MSH and NPY.  
Post-EAU RPE CM Effect on Phagolysosome Activation 
 To see if there is a change in RPE suppression of phagolysosome activation in 
EAU, and to see if therapies that suppress EAU promote RPE suppression of 
phagolysosome activation, mice were immunized to induce EAU and then treated with 
PBS, MC5r agonist, or α-MSH. Extraction and preparation of eyecups began only after 
the treated mice, excluding PBS treated mice, were fully recovered from EAU. 
Phagolysosome activity assay was assayed, as done in the previous studies, and 
macrophages were assessed for fluorescence via fluorescent microscopy (Figure 7).  
A.      B. 
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Figure 7. Images of macrophages treated with RPE CM from EAU and post-EAU mice. (A) Image of 
untreated macrophages at rest without pHrodo bioparticles. (B) Image of untreated macrophages with 
pHrodo-red bioparticles. Images are taken from two different experiments with same exposure settings. 
C.      D. 
          
Figure 7C-D. (C) Image of macrophages with RPE CM from non-immunized mice. (D) Image of 
macrophages with RPE CM from PBS treated EAU mice. Images are taken from two different experiments 
with same exposure settings. 
E.      F. 
          
Figure 7E-F. (E) Image of macrophages with RPE CM from MC5r Agonist treated EAU mice. (F) Image 
of macrophages with RPE CM from α-MSH treated EAU mice. 
The untreated macrophages showed phagolysosome activation as indicated by a 
bright red fluorescence (Figure 7B). Macrophages treated by RPE CM from the non-
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immunized mice, therefore did not develop EAU, showed suppression of macrophage 
phagolysosome activation (Figure 7C). Although EAU mice treated with MC5r agonist 
seemed to fully recover, macrophages treated with RPE CM from mice treated with 
MC5r agonist did not show a significant suppression (Figure 7D). This was also 
statistically confirmed (Figure 8) as there was not a statistical difference between the 
relative CTCF expressed from this group and relative CTCF expressed in macrophages 
with RPE CM from mice who were treated with PBS (the mice that had not recovered 
from EAU). However, macrophages treated with RPE CM from EAU mice treated with 
α-MSH did show suppression of phagolysosome activation (Figure 7E). This is also 
confirmed as there was a statistical difference, P<0.05, between the relative CTCF 
expressed by macrophages with RPE CM from EAU mice treated with PBS and the 
relative CTCF expressed by macrophages with RPE CM from EAU mice treated with α-
MSH (Figure 9). 
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Figure 8. The effects of RPE CM from EAU and post-EAU mice on phagolysosome activity. Shown is 
the relative CTCF ± SEM of pHrodo-red expression in the RPE CM from EAU mice treated with PBS or 
MC5r agonist. Data is from two separate experiments, N=4. There were no significant difference between 
relative CTCF expressed by macrophages with RPE CM from PBS treated EAU mice and MC5r Agonist 
treated EAU mice. *There was significant difference between relative CTCF expressed by macrophages 
with RPE CM from healthy mice and PBS Treated EAU mice (p<0.0001) as well as MC5r agonist treated 
EAU mice (p<0.0001). 
 
Figure 9. The effects of RPE CM from EAU and post-EAU mice on phagolysosome activity. Shown is 
the relative CTCF ± SEM of pHrodo-red expression in the RPE CM from EAU mice treated with PBS or α-
MSH. N=3. There was no significant difference between α-MSH treated EAU mice and non-immunized 
mice. *There was significant differences between untreated mice and non-immunized mice, non-
immunized mice and PBS treated EAU mice, PBS treated EAU mice and α-MSH treated post-EAU mice, 
and untreated and α-MSH treated post-EAU mice (p<0.0001). 
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Cytokines Involved in Phagolysosome Activation  
To identify and measure the cytokines that may be involved in RPE CM ability to 
down regulate phagolysosome activation in primary macrophages, a mouse cytokine 
array assay was used on RPE CM extracted from non-immunized mice, PBS treated EAU 
mice, MC5r agonist treated post-EAU mice, and α-MSH treated post-EAU mice. The 
Quantibody Mouse Cytokine Array kit was used to assess for twenty different mouse 
cytokines and have similar detection sensitivity as a traditional ELISA. Array kit 
included a glass chip with embedded array support. After addition of RPE CM to this 
glass chip and respective incubation periods, a cocktail of Biotin-Ab is added to detect 
the RPE CM that had interacted with the cytokine array. Following incubation, labeled 
streptavidin-labeled Cy3 was added so that fluorescence may be detected only with the 
cytokine-antibody-biotin complex. After washing the glass chip thoroughly, images were 
taken at 50.05 seconds exposure and analyzed using the Quantity One software from Bio-
Rad Laboratories (Figure 10).  
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Figure 10. Image of cytokine array glass chip. Image was taken at an exposure time of 50.05 seconds. 
The top row is the cytokine standards at various dilutions—the standards becoming less dilute from left to 
right and the first being the negative control (#1). The first two dilutions (#2,3) were unable to be analyzed 
due to low density. Standards were used to convert density (INT/mm2) to concentration (ng/ml). 
	   The top row of the array glass chip shows the cytokine standards at multiple 
dilutions. The least diluted standard, array #8, had standard concentration of 4,000	  pg/ml 
of IL-6, 2,000 pg/ml of KC and 4,000 pg/ml of VEGF. These concentrations correlated to 
a density of	  309142.17 INT/mm2 of IL-6, 178166.12 INT/mm2 of KC and 219308.92 
INT/mm2 of VEGF (INT: Intensity).	  The most diluted standard that could be detected, 
fourth from the top left, had concentrations of 49 pg/ml of IL-6, 25 pg/ml of KC and 49 
pg/ml of VEGF.  These more dilute concentrations correlated to a density of 162555.78 
INT/mm2 of IL-6, 159512.89 INT/mm2 of KC and 163296.42 INT/mm2 of VEGF. 
Fluorescence indicated that all RPE CM consisted of high concentrations of IL-6. There 
is also evidence of keratinocyte-derived cytokine (KC) and trace amounts of VEGF.  
Table 2. Mouse Cytokine Densities and Concentrations  
Sample Cytokine Density 
(INT/mm2) 
Standard 
Concn 
(pg/ml) 
Non-Immunized IL-6 587561.8873 7.069 
  KC 201356.4456 NA* 
  VEGF 185471.423 0.995 
Non-Immunized IL-6 632602.7022 7.615 
  KC 192011.2846 3.973 
  VEGF 175565.1733 1.25 
PBS Treated IL-6 604654.4037 7.276 
  KC 196759.6716 4.16 
  VEGF 179034.8161 1.152 
PBS Treated IL-6 690346.9182 8.316 
  KC 196586.2845 4.153 
	  30 
  VEGF 196214.2799 0.776 
MC5r Antagonist Treated IL-6 618916.9884 7.449 
  KC 184230.6397 3.633 
  VEGF 171132.1378 1.397 
MC5r Antagonist Treated IL-6 557020.3916 6.699 
  KC 189591.9298 3.872 
  VEGF 176644.6376 1.218 
α-MSH Treated IL-6 477997.2647 5.74 
  KC 185444.3493 3.689 
  VEGF 172156.2449 1.36 
α-MSH Treated IL-6 515912.9098 6.2 
  KC 175180.6399 3.159 
  VEGF 169334.8164 1.468 
*Could not be determined; value exceeded standard curve. 
These conversions of cytokine standards to the densities analyzed from the glass 
chip were then interpolated into individual concentrations based off of the best-fit 
standard curve (Table 2). IL-6 showed an average concentration of 26,489 ng/ml in RPE  	  
  
Figure 11. Mouse cytokine IL-6 concentration in RPE CM of EAU and post-EAU mice. Graph shows 
average concentration levels ±SEM. There was an average IL-6 concentration of 26,489±1,4765 ng/ml in 
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RPE CM of non-immunized mice, 112,951±94,053 ng/ml in RPE CM of PBS treated EAU mice, 
16,572±11,576 ng/ml in RPE CM of MC5r agonist treated post-EAU mice, and 1,067±517.5 ng/ml in RPE 
CM of α-MSH treated post-EAU mice. 
 
Figure 12. Mouse cytokine KC concentration in RPE CM of EAU and post-EAU mice. Graph shows 
average concentration levels ±SEM. There was an average KC concentration of 9.391±0 ng/ml in RPE CM 
of non-immunized mice, 14.34±0.1091 ng/ml in RPE CM of PBS treated EAU mice, 5.872±1.576 ng/ml in 
RPE CM of MC5r agonist treated post-EAU mice, and 3.166±1.724 ng/ml in RPE CM of α-MSH treated 
post-EAU mice. 
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Figure 13. Mouse cytokine VEGF concentration in RPE CM of EAU and post-EAU mice. Graph 
shows average concentration levels ±SEM. There was an average VEGF concentration of 
0.01383±0.003955 ng/ml in RPE CM of non-immunized mice, 0.01008±0.004114 ng/ml in RPE CM of 
PBS treated EAU mice, 0.02075±0.004219 ng/ml in RPE CM of MC5r agonist treated post-EAU mice, and 
0.02616±0.003229 ng/ml in RPE CM of α-MSH treated post-EAU mice. 
CM of non-immunized mice, 112,951 ng/ml in RPE CM of PBS treated EAU mice, 
16,572 ng/ml in RPE CM of MC5r agonist treated post-EAU mice, and 1,067 ng/ml in 
RPE CM of α-MSH treated post-EAU mice. KC showed average concentrations of 
approximately 9.39 ng/ml in RPE CM of non-immunized mice, 14.34 ng/ml in RPE CM 
of PBS treated EAU mice, 5.87 ng/ml in RPE CM of MC5r agonist treated post-EAU 
mice, and 3.17 ng/ml in RPE CM of α-MSH treated post-EAU mice. Finally, VEGF 
showed average concentrations of approximately 0.01 ng/ml in RPE CM of non-
immunized mice, 0.01ng/ml in RPE CM of PBS treated EAU mice, 0.02 ng/ml in RPE 
CM of MC5r agonist treated post-EAU mice, and 0.03 ng/ml in RPE CM of α-MSH 
treated post-EAU mice. These results are shown in Figures 11-13. Though VEGF 
	  33 
concentrations seem to be very miniscule, cytokine IL-6 and KC may be worth further 
investigation particularly because others have suggested that IL-6 may be an important 
mediator of inflammation in the eye (Ohta et al., 2000).  
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DISCUSSION 
 
 The results further demonstrated that RPE play an important part in the regulation 
of macrophage activity, and thus overall maintenance of immunosuppression in the eye. 
RPE CM significantly reduced, P<0.0001, the activation of phagolysosomes in 
macrophages that phagocytized opsonized bacterial bioparticles. This suppression was 
mediated by RPE cells producing soluble neuropeptides α-MSH and NPY. 
 Depletion of RPE CM of certain neuropeptides helped look into mechanisms 
behind RPE reduction of phagolysosome activation. The depletion of α-MSH, NPY and 
α-MSH + NPY caused an almost complete lack of fluorescence. A result like this would 
signified that the phagolysosome activation in macrophages was suppressed; but, these 
macrophages also displayed an altered appearance. The results showed that macrophages 
treated with RPE CM depleted of α-MSH and NPY were predominately dead. This is 
supported by previous studies that established the importance of these neuropeptides to 
macrophage viability (Kawanaka & Taylor, 2011; Phan & Taylor, 2013; A. W. Taylor, 
2013). Because viability was compromised in these macrophages, α-MSH and NPY role 
on the down-regulation of macrophage phagolysosome activity could not be fully 
assessed in the current study.  
 The most used model of intraocular inflammatory disease is the murine EAU 
model (Gery et al., 1986; Schalken et al., 1988). The murine models have shown to be 
valuable in many ways. One major reason is that pathologically, the nature and 
progression of uveal disease is very similar to human ocular inflammatory disease. 
Further, once immunized with EAU, the active stage of the disease is rather long in 
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duration. This allows for more freedom for therapeutic experimentation (Caspi et al., 
1988). As such many have studied mechanisms before and during disease but few have 
looked at the mechanisms post-recovery.  
The next part of the current study thus looked into the effects of RPE CM 
collected from EAU and post-EAU mice on phagolysosome activation of primary 
macrophages.  Results revealed that while RPE CM from non-immunized mice caused 
suppression of phagolysosome activation in macrophages as we have previously seen, 
RPE CM from PBS treated mice did not cause a significant suppression of 
phagolysosome activity. This indicated that during active EAU, RPE CM lost its ability 
to down-regulate phagolysosome activity. What is more interesting is that RPE CM from 
α-MSH treated post-EAU mice did recover its ability to suppress phagolysosome activity 
in the macrophage; however, RPE CM from MC5r agonist treated mice—fully recovered 
post-EAU mice—did not cause a significant suppression in macrophage phagolysosome 
activity. This implied that, even though the mice may fully recover from EAU, MC5r 
agonist treatment does not recover RPE’s ability to down-regulate phagolysosome 
activity in the macrophage. It also suggested that α-MSH, though also acts as a MC5r 
agonist, may cause reduction of phagolysosome activity through other melanocortin 
receptors or may even require mechanisms in addition to MC5r stimulation. The results 
direct us to think that α-MSH may be required for the recovery of inflammation and 
further study would be beneficial.   
Past research has shown that during active uveitis in humans, there is a significant 
amount secretion of pro-inflammatory cytokines and chemokines in the intraocular 
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environment (Curnow & Murray, 2006). Similar cytokines are seen in EAU murine 
model. However, we know little about the cytokines involved when immunosuppression 
is lost. To further comprehend the components of immunosuppressive activity of the 
macrophage by RPE before, during and post-EAU, a mouse cytokine array assay was 
performed on RPE CM taken from non-immunized mice, EAU, and post-EAU mice.  
Results showed that out of the twenty cytokines that the assay could have 
detected, IL-6, KC, and VEGF were the only mouse cytokines that were identified in all 
RPE CM regardless of EAU stage. Among the three cytokines that were detected, it is 
interesting to note that IL-6 was present in extreme concentrations, particularly in the 
RPE CM from EAU mice that were treated with PBS that showed little to no suppression 
of phagolysosome activation. This is congruent with past findings that suggests that IL-6 
acts as a pro-inflammatory factor in the intraocular environment and is present in high 
concentrations in the aqueous humor during active EAU and suppression of inflammation 
from an anti-inflammatory agent also showed decreases in IL-6 concentration (Qin et al., 
2014).  
   Cytokine KC (also known as keratinocyte chemoattractant) was also present in 
all RPE CM although not as high in concentration as IL-6. Results also showed that KC 
was in higher concentration in RPE CM extracted from EAU mice treated by PBS. This 
may be because KC is a chemokine that is involved in chemotaxis and neutrophil 
activation. This is not unusual as KC has been reported to be involved with the 
recruitment and activation of neutrophils into areas of high inflammation (Huang, 
Paulauskis, Godleski, & Kobzik, 1992). VEGF was also detected but at very minimal 
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concentrations.  Perhaps further study can elucidate IL-6 as well as KC and VEGF 
involvement in the immunosuppressive response of macrophages. 
Past study has demonstrated the specific importance of neuropeptides α-MSH and 
NPY on phagocytosis and phagolysosome activity to the resident macrophage (Phan & 
Taylor, 2013). It has also been discovered that the RPE, among other parts of the retina 
such as amacrine cells of the inner nuclear and ganglion cell layer, is an important source 
of both these neuropeptides (Kawanaka & Taylor, 2011). The current study has further 
illustrated the importance of the RPE in phagolysosome regulation of the primary 
macrophage. Also found was that both α-MSH and NPY produced by the RPE are 
essential to RPE regulation of phagolysosome activation.  
Further studies into ocular immune privilege should reveal other mechanisms for 
regulating immunity that may find clinical value. There exists multiple publications 
showing the appeal in implementing α-MSH as a form of peptide or gene therapy to 
suppress maladies such as uveitis, septic shock, hypersensitivity, multiple sclerosis and 
allograft survival (Gatti S, Colombo G, Buffa R, et. al., 2002; Thomas A Luger & 
Brzoska, 2007; Mirotti, Castro, Costa-Pinto, & Russo, 2010; A. W. Taylor & Lee, 2010). 
Most of these current treatments are restricted to steroids; however, with the use of an 
immunomodulating neuropeptide such as α-MSH, perhaps a remedy with efficacy and 
less side effects is achievable. It would be interesting to see what clinical applications 
arise with these current discoveries. 
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